Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

EuroIntervention

Volumn 9, Issue 3, 2013, Pages 308-315

  Meredith, Ian T ^a   Verheye, Stefan ^b   Weissman, Neil J ^c   Barragan, Paul ^d   Scott, Douglas ^e   Chávarri, Mariano Valdés ^f   West, Nick E J ^g   Kelbaek, Henning ^h   Whitbourn, Robert ⁱ   Walters, Darren L ^j,r   Kubica, Jacek ^k   Thuesen, Leif ^l   Masotti, Monica ^m   Banning, Adrian ⁿ   Sjogren, Iwar ^o   Stables, Rod H ^p   Allocco, Dominic J ^q   Dawkins, Keith D ^q  

^a SOUTHERN HEALTH   (Australia)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c MedStar Health Research Institute Washington   (United States)

^d Polyclinique les Fleurs   (France)

^e MIDDLEMORE HOSPITAL   (New Zealand)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^g PAPWORTH HOSPITAL   (United Kingdom)

^h Rigshospitalet   (Denmark)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j THE PRINCE CHARLES HOSPITAL   (Australia)

^k NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m UNIVERSITY OF BARCELONA   (Spain)

ⁿ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^o FALUN HOSPITAL   (Sweden)

^p LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^q BOSTON SCIENTIFIC CORPORATION   (United States)

^r UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

Bioabsorbable polymer; Coronary stenosis; Drug eluting stents; Everolimus; Transluminal percutaneous coronary intervention

Indexed keywords

EVEROLIMUS; POLYGLACTIN;

ARTICLE; BIODEGRADABLE IMPLANT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MATERIAL COATING; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; TREATMENT OUTCOME;

EID: 84880870416     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9I3A52     Document Type: Article

References (32)

1. Palmerini T, Biondi-Zoccai G, Riva DD, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim H-S, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet.2012:379:1393-402.
2. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368:254-65.
3. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-34.
4. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-30.
5. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399-409.
6. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-81.
7. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schomig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2:291-9.
8. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Juni P, Virmani R, Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391-9.
9. Curcio A, Torella D, Cuda G, Coppola C, Faniello MC, Achille F, Russo VG, Chiariello M, Indolfi C. Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. Am J Physiol Heart Circ Physiol. 2004;286:H902-8.
10. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500-10.
11. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation. 2007;115:1051-8.
12. Pendyala LK, Li J, Shinke T, Geva S, Yin X, Chen JP, King SB 3rd, Robinson KA, Chronos NA, Hou D. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. JACC Cardiovasc Interv. 2009;2:253-62.
13. Silva GV, Fernandes MR, Madonna R, Clubb F, Oliveira E, Jimenez-Quevedo P, Branco R, Lopez J, Angeli FS, Sanz-Ruiz R, Vaughn WK, Zheng Y, Baimbridge F, Canales J, Cardoso CO, Assad JA, Falotico R, Perin EC. Comparative healing response after sirolimus-and paclitaxel-eluting stent implantation in a pig model of restenosis. Catheter Cardiovasc Interv. 2009;73:801-8.
14. Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carrie D, Walsh S, Oldroyd KG, Varenne O, El-Jack S, Moreno R, Joshi AA, Allocco DJ, Dawkins KD. Primary endpoint results of the EVOLVE trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59:1362-70.
15. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57:1700-8.
16. Wilson GJ, Huibregtse BA, Pennington DE, Dawkins KD. Comparison of the SYNERGY with the PROMUS (XIENCE V) and bare metal and polymer-only Element control stents in porcine coronary arteries. EuroIntervention. 2012;8:250-57.
17. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37:1478-92.
18. Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, Kaltoft A, Maeng M, Kristensen SD, Bøtker HE, Terkelsen CJ, Villadsen AB, Ravkilde J, Aarøe J, Madsen M, Thuesen L, Lassen JF. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): A randomised non-inferiority trial. Lancet. 2013;381:661-9.
19. Smits PC, Hofma S, Togni M, Vázquez N, Valdés M, Voudris V, Slagboom T, Goy JJ, Vuillomenet A, Serra A, Nouche RT, den Heijer P, van der Ent M. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): A randomised, controlled, non-inferiority trial. Lancet. 2013;381:651-60.
20. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schomig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: A pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214-22.
21. Klauss V, Serruys PW, Pilgrim T, Buszman P, Linke A, Ischinger T, Eberli F, Corti R, Wijns W, Morice MC, Di Mario C, van Geuns RJ, van Es GA, Kalesan B, Wenaweser P, Jüni P, Windecker S. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice. JACC Cardiovasc Interv. 2011;4:887-95.
22. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice M-C, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378:1940-8.
23. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51:172-209.
24. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501-55.
25. Navarese EP, Kubica J, Castriota F, Gibson M, De Luca G, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: Evidence from a meta-analysis of randomised trials. EuroIntervention. 2011;7:985-94.
26. Abizaid AA. EXCELLA BD Randomized Trial 6-month Resuts. Presented at: TCT; November 8, 2011; San Francisco, CA, USA.
27. Dani S. Abluminus DES enABL Program Update. Presented at: TCT; October 23, 2012; Miami, FL, USA.
28. Ostojic M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N, Nedeljkovic M, Mangovski L, Milosavljevic B, Stojkovic S, Orlic D, Antonic Z, Miloradovic V, Topic D, Paunovic D. First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: NOBORI CORE nine months angiographic and one year clinical outcomes. EuroIntervention. 2008;3:574-79.
29. Pomeranz M. Sirolimus-eluting coronary stent utilising a fully bioabsorbable drug carrier and integrated delivery system. Presented at: EuroPCR; May 17, 2012; Paris, France.
30. Windecker S. Biosensors' BioMatrix Biolimus A9-eluting Stent: Technical Review and Clinical Trial Update. Presented at: TCT; October 21, 2007; Washington, DC, USA.
31. Windecker S. The Biosensors BIOMATRIX Clinical Trial Program Update, Featuring the LEADERS Trial. Presented at: TCT; October 13, 2008; Washington, DC, USA.
32. Windecker S. Orsiro (BIOTRONIK) Program Update. Presented at: TCT; October 23, 2012; Miami, FL, USA.